Organometallic compounds have been extensively used for cancer treatment over the past few decades. However, major clinical problems, including high toxicity to normal healthy cells, low selectivity, and acquired or intrinsic resistance, often lead to the fail of complete cancer remission and numerous undesirable side effects. In order to overcome these problems, we designed and synthesized new organometallic compounds based on ferrocene, ruthenium metals with indole, resorcinol, PTA derivatives. Currently, these compounds are at the stage of in vitro testing for anticancer activity. These compounds are furnished with functional groups which expected to induce programmed cell death and show high selectivity to cancer cells. Furthermore, to reduce the toxicity and to deliver an anticancer agent directly to the target cell we will encapsulate synthesized complexes with the synthetic biodegradable and biocompatible polymers. With further studies we wish to examine the mode of actions of compounds to see the interaction with DNA and impact on the cell cycle.

Synthesis,<i> in vitro</i> testing, and encapsulation of novel organometallic compounds for cancer treatment

247th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.

Synthesis, in vitro testing, and encapsulation of novel organometallic compounds for cancer treatment